December 30, 2024 — Guangzhou Ruifeng Biotechnology Co., Ltd. announced the successful completion of a new round of financing worth hundreds of millions of RMB. This round was led by Guangzhou Industrial Investment Fund, with participation from Guangzhou Finance Holdings, Science and Finance Holdings, and existing shareholder GZY Capital among other institutions. The funds will primarily be used to advance Ruifeng Biotech’s gene-editing drug clinical trials, expand subsequent R&D pipelines, and promote core technological innovation.

Read the original text

On December 23, the Anhui Medical Products Centralized Procurement Platform released the "Notice of the Winning Results of the Centralized Volume-based Procurement of Intracranial Stents, Thrombectomy Stents, and Flow Diverter Dense Mesh Stents for Medical Devices in Anhui Province." AccuMedical's Lattice® Flow Diverter Dense Mesh Stent was successfully selected!

Read the Original Text

Following the launch of China's first shock wave system C-Wave® in June 2023, HuiHe Healthcare has recently introduced the C-Wave® intravascular shock wave catheter, compatible with a .018" guidewire system, and has officially received approval from the National Medical Products Administration (NMPA) for market release! With this, HuiHe Healthcare’s C-Wave® becomes the first intravascular shock wave system in China to simultaneously feature both .014" and .018" guidewire systems, while also addressing both peripheral and coronary applications.

Read the Original Text

Recently, the Shanghai Science and Technology Commission announced the "Shanghai Biomedical 'New Excellent Medical Devices' Product Catalog" (Fourth Batch). The product artificial ligament and accessories by Ligatech successfully made it into the "New Excellent Medical Devices" Product Catalog.

Read the Original Text

Recently, Alipay announced the launch of the Commercial Insurance Code, aiming to create a one-stop payment experience for medical insurance and commercial insurance. After patients use their medical insurance for hospital payments, if additional coverage is needed, they can directly use the Commercial Insurance Code to apply for an advance payment of hospital expenses and later file a reimbursement claim with the insurance company. The first phase of the Commercial Insurance Code has already covered mainstream million-yuan medical insurance policies from Taikang Online, serving nearly 10 million users.

It is reported that the commercial insurance code cooperated by Alipay and Taikang Online this time is provided with important technical and service support by MediTrust Health. Users can activate the commercial insurance code payment after applying for the activation of the commercial insurance code. The technical and service support provided by MediTrust Health this time benefits from the one-code direct payment™ product capability of MediTrust Health. According to the data, the one-code direct payment™ platform is a one-stop medical payment platform launched by MediTrust Health in February this year, which has pioneered a new format of "commercial insurance payment by code scanning".

Read the Original Text

On December 25, 2024, the expandable sheath kit independently developed by Chengdu NewMed Biotechnology Co., Ltd. was approved for marketing by the Sichuan Provincial Drug Administration.

Read the Original Text

Recently, in order to meet the demand for the application of gene sequencing technology in daily testing work and enhance the overall level of testing technology analysis and scientific research capabilities, the Lhasa Center for Disease Control and Prevention in the Tibet Autonomous Region (hereinafter referred to as "Lhasa CDC") has introduced the QPursue-6khex mid-throughput nanopore gene sequencing platform and the QPrenano-100 fully automatic sample preparation system from Qigen Technology. This represents an important step forward for the Lhasa CDC in disease prevention and control, public health monitoring, health supervision enforcement, and scientific research capabilities.

Read the original text

Recently, Tendfast™ Peripheral Venous Thrombectomy Stent System (NMPA Approval No. 20243032574), independently developed by Tengfu Medical, has been approved for marketing by the National Medical Products Administration (NMPA)!

Read the Original Text

Read the Original Text

Read the Original Text

Recently, BPR-30221616 Injection, a Class 1 new drug independently developed by Chengdu Bright Future Pharmaceutical Co., Ltd., intended for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), has officially been approved by the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) and will initiate clinical trials in the near future.

Read the Original Text

HaiChuang Pharma (688302.SH) has recently submitted supplementary materials for the new drug marketing application of Deuterated Enzalutamide Soft Capsules (Project No.: HC-1119) as required by the CDE. It has now entered the technical review stage. The company's team will maintain active communication with the CDE to strive for the early completion of the new drug marketing review process.

Read the Original Text

On December 11, 2024, the IND application for EXG110 Injection, independently developed by Hangzhou Jiayin Biotechnology, was approved by the National Medical Products Administration (NMPA) for conducting clinical trials to treat Fabry Disease.

Read the Original Text

Recently, the national science and technology major project jointly applied for by AccuMedical has been officially approved for establishment. The project is led by Sichuan University, with participating institutions including West China Hospital of Sichuan University, Shanghai Jiao Tong University, Zhejiang University, China University of Geosciences, and the Research Center for Eco-Environmental Sciences of the Chinese Academy of Sciences, among other top medical institutions, universities, and research institutes in China.

This special project focuses on the goal of "acquiring resources, ensuring safety, and creating space" in the deep underground, aiming to provide health assurance for deep underground development. AccuMedical will collaborate with partner organizations to jointly map the deep underground microbiome and genome, providing strategic support for exploring deep Earth resources.

Read the Original Text

In December 2024, the Beijing Municipal Science and Technology Commission and the Zhongguancun Science Park Management Committee released the "Notice on the Public Announcement of the Proposed List of Key Laboratories of Beijing Municipality for 2024." The Beijing Key Laboratory of "Intelligent Creation of Synthetic Biological Manufacturing Elements," jointly established by MicroMeta Synthesis, the Institute of Microbiology of the Chinese Academy of Sciences, the China Food Fermentation Industry Research Institute of Poly Zhongqing, and the COFCO Nutrition and Health Research Institute, was approved.

Read the Original Text

On December 9, 2024, Ms. Maryam Nawaz Sharif, Chief Minister of Punjab Province—the most populous and economically strongest province in Pakistan—led a delegation of more than 20 members, including representatives from the Embassy of Pakistan in China, the Information Department, Ministry of Industry, Ministry of Finance of Punjab Province, as well as banking industry representatives, to visit HuiHe Healthcare for an inspection. Mr. Lin Tao, Deputy Director of the First Bureau of the Central Liaison Department, also attended the event.

Read the Original Text